Massachusetts General Hospital
Boston, MA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Not yet accepting
KarMMa-9
Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant
Learn more- CAR T Cell
- Immunomodulatory Drug
- BCMA
- Randomization
- Phase 3
Accepting patients
MonumenTAL-3
Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsNot currently accepting
KarMMa-2
Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- High Risk
- Phase 2
Accepting patients
Bone Marrow & Kidney Transplant
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Daratumumab Combination Therapy
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Learn more- Monoclonal Antibody
- Proteasome Inhibitor
- CD38
- Phase 2
- CAR T Cell
- APRIL
- BCMA
- Phase 1
Accepting patients
PEACE
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy (PEACE)
Learn more- Randomization
- Phase 0
Not yet accepting
ISABELA
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Learn more- Monoclonal Antibody
- CD38
- Quadruplet Therapy
- Phase 2
Accepting patients
Elranatamab as Consolidation
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- CD3
- Phase 2
Accepting patients
CaMMouflage
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn more- CAR T Cell (Allogeneic)
- BCMA
- Phase 1